LIS Technologies Announces $6.2M Acquisition of the 37,800sq-ft K-1580 Facility at the Historic Heritage Center in Oak Ridge, Tennessee to Expand its Medical and Stable Isotope and Nuclear Fuel Cycle Initiatives
Oak Ridge, Tennessee--(Newsfile Corp. - August 12, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a developer of proprietary advanced laser technology and the only USA-origin and patented laser uranium enrichment company, is pleased to announce that it has expanded its presence in Oak Ridge, Tennessee's historic Heritage Center and K-25 Enrichment Site with the acquisition of the K-1580 Building, a prominent, newly-renovated, three-level, 37,803 square-foot facility, for a to
Technologies, Mines et métaux, Énergie, Santé
2026-08-12 8:59 AM EDT | LIS Technologies Inc.
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnologies, Pharmaceutique, Santé
2026-08-12 8:23 AM EDT | Hemostemix Inc.
Experience Onward Acquires 36 Acre Colorado Property to Launch Onward Ranch, a Legal Psilocybin and Wellness Retreat Destination
Denver, Colorado--(Newsfile Corp. - August 11, 2026) - Experience Onward, founded by former NHL player and two time Stanley Cup champion Daniel Carcillo, today announced the acquisition of a private, 36 acre mountain property in Colorado that is now progressing through the state licensing process to become a legal psilocybin retreat destination. Named Onward Ranch, the property is being developed as a first of its kind residential retreat environment designed to bring legal, regu
2026-08-11 9:00 AM EDT | Experience Onward
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m. to both in-person students and those joining live online.
Soins de santé et hôpitaux, Santé
2026-08-11 8:00 AM EDT | Adia Med Inc.
ONE HEMP Welcomes Senate Continuing Resolution Passage, Calls for Clear Distinctions in Hemp Policy
Washington, D.C.--(Newsfile Corp. - August 11, 2026) - ONE HEMP welcomed the Senate's passage of a continuing resolution extending naturally-occurring hemp product ban until December 11, preventing a broad restriction on full-spectrum hemp products from taking effect on November 12 and providing Congress additional time to advance sound, science-based legislation. The extension creates an opportunity for lawmakers to develop a regulatory framework that protects consumers while pr
2026-08-11 7:23 AM EDT | OneHemp
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnologies, Pharmaceutique, Santé
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue gener
Technologies, Biotechnologies, Santé
2026-08-11 6:00 AM EDT | Restart Life Sciences Corp.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnologies, Pharmaceutique, Santé
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company's financial and o
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-10 4:54 PM EDT | Elite Pharmaceuticals, Inc.
Tersis Technologies Files Current Report to Update Corporate Reference Data, Highlighting Shift to Clean-Technology and Circular-Infrastructure Business
Brooksville, Florida--(Newsfile Corp. - August 10, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a clean-technology company focused on transforming waste streams into valuable resources, today announced that it has filed a Current Report through the OTC Markets Disclosure & News Service to formally update its corporate reference record and business description with OTC Markets, licensed reference-data vendors, and financial media outlets. The Current R
Agriculture, Énergie, Énergies de substitution, Santé
2026-08-10 10:58 AM EDT | Tersis Technologies Inc.
Mobile-health Network Solutions Advances AI-Powered Lab Data Analysis to Transform Clinical Decision-Making
Singapore, Singapore--(Newsfile Corp. - August 10, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health ecosystem headquartered in Singapore, today announced the development of a next-generation AI-powered lab data analysis solution designed to help clinicians rapidly interpret complex longitudinal laboratory data and improve patient care outcomes at scale. Developed through its subsidiary Skylink I
2026-08-10 9:00 AM EDT | Mobile-health Network Solutions
Charlotte's Web Welcomes Senate Passage of Hemp Extension Marking Important Progress Toward a Long-Term Federal Hemp Framework
Louisville, Colorado--(Newsfile Corp. - August 10, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF), a botanical wellness innovation company and the market leader in hemp-derived cannabidiol (CBD) extract wellness products, today welcomed the U.S. Senate's passage of its Continuing Resolution (CR), which would extend current government funding through December 11, 2026, and provide Congress additional time to finish developing a bipartisan federal framework for hemp.
2026-08-10 8:23 AM EDT | Charlotte's Web Holdings, Inc.
TelyRx Announces Second Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - August 10, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and digital pharmacy platform, today announced financial results for the second quarter ended June 30, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the Second Quarter of 2026 Revenue increased to $22.7 million, compare
Soins de santé et hôpitaux, Santé
2026-08-10 7:00 AM EDT | TelyRx
Rise Nano Optics Announces Frankfurt Stock Exchange Listing
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange
2026-08-10 7:00 AM EDT | Rise Nano Optics Ltd.
Extendicare Announces 2026 Second Quarter Results
Markham, Ontario--(Newsfile Corp. - August 6, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and six months ended June 30, 2026. Second Quarter 2026 Highlights Adjusted EBITDA(1) increased by $28.5 million or 71.7% from Q2 2025 to $68.3 million, driven primarily by contributions from the acquisitions of CBI Home Health and Closing the Gap, as well as continued
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-06 5:00 PM EDT | Extendicare Inc.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-06 4:05 PM EDT | Phio Pharmaceuticals Corp.
WELL Health Achieves Record Quarterly Revenue Milestone of $400 Million in Q2-2026, Driven by 32% Revenue Growth of Canadian Patient Services, and Raises 2026 Annual Guidance
WELL achieved quarterly revenues of $400.4 million in Q2-2026, an increase of 12% as compared to Q2-2025, driven by strong growth in the Company's Canadian Patient Services Business where quarterly revenue increased by 32% to $151.6 million in Q2-2026 as compared to Q2-2025. WELL achieved Adjusted EBITDA(1) of $48.1 million in Q2-2026, a decrease of 3% as compared to Q2-2025, representing an Adjusted EBITDA Margin(1) of 12%. The decrease reflects the impact
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-08-06 4:00 PM EDT | WELL Health Technologies Corp.
Jones Healthcare Group Expands Integrated Packaging Capabilities With Thermoforming Acquisition
London, Ontario--(Newsfile Corp. - August 6, 2026) - Jones Healthcare Group has acquired an operating thermoforming facility and related business assets in Brampton, Ont., adding in-house production of custom-formed packaging components to its integrated offering. The acquisition includes the facility, equipment and an experienced team of colleagues who will join Jones Healthcare. The addition complements the company's existing expertise in printed packaging components, contract packagi
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-06 10:30 AM EDT | Jones Healthcare Group